These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Witzig TE Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398 [TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Alcindor T; Witzig TE Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764 [TBL] [Abstract][Full Text] [Related]
24. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. Clayton J Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742 [TBL] [Abstract][Full Text] [Related]
25. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Witzig TE Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003 [TBL] [Abstract][Full Text] [Related]
26. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Grillo-López AJ Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025 [TBL] [Abstract][Full Text] [Related]
27. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755 [TBL] [Abstract][Full Text] [Related]
28. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS; Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803 [TBL] [Abstract][Full Text] [Related]
29. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962 [TBL] [Abstract][Full Text] [Related]
30. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315 [TBL] [Abstract][Full Text] [Related]
31. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191 [TBL] [Abstract][Full Text] [Related]
32. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981 [TBL] [Abstract][Full Text] [Related]
34. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494 [TBL] [Abstract][Full Text] [Related]
35. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Gregory SA Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399 [TBL] [Abstract][Full Text] [Related]
36. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related]
37. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Hagenbeek A; Lewington V Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280 [TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Evens AM; Gordon LI Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144 [TBL] [Abstract][Full Text] [Related]
39. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Bischof Delaloye A Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740 [TBL] [Abstract][Full Text] [Related]
40. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma. Jacobs SA; Harrison AM; Swerdlow SH; Foon KA; Avril N; Vidnovic N; Joyce J; DeMonaco N; McCarty KS Mol Imaging Biol; 2009; 11(1):39-45. PubMed ID: 18773247 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]